Autolus Therapeutics
AUTL
43 hedge funds and large institutions have $167M invested in Autolus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 9 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 46 → 43 (-3)
10.89% less ownership
Funds ownership: 29.33% → 18.44% (-11%)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
77% less capital inflows, than outflows
Capital inflows: $32.4M | Capital outflows: $139M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jupiter Asset Management
London,
United Kingdom
|
+$9.32M |
| 2 |
Millennium Management
New York
|
+$8.3M |
| 3 |
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$3.97M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$2.62M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodford Investment Management
London,
United Kingdom
|
-$126M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.91M |
| 3 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.86M |
| 4 |
Sand Grove Capital Management
London,
United Kingdom
|
-$1.63M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.15M |
AUTL Hedge Fund Activity: Q3 2019 in Review
43 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2019, worth a combined $167M — down 51% from $344M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AUTL and 6 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 16 added.
The largest buyer was Jupiter Asset Management, opening a new position worth an estimated $9.32M. The largest seller was Woodford Investment Management, cutting an estimated $126M.
- 43 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2019, down from 46 in Q2 2019.
- Funds reported $167M of Autolus Therapeutics stock for Q3 2019, down 51% quarter-over-quarter.
- 6 funds opened new Autolus Therapeutics positions in Q3 2019 and 9 closed out, a net change of -3 holders.
- The largest Autolus Therapeutics buyer in Q3 2019 was Jupiter Asset Management, an estimated $9.32M added.
- The largest Autolus Therapeutics seller in Q3 2019 was Woodford Investment Management, an estimated $126M sold.
Based on aggregated 13F filings for Q3 2019.